Want to see PFSA full AI Analyst Report?
Top Page
Profusa
(NASDAQ:PFSA)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▼(-70.00% Downside)
Action:Reiterated
Date:09/30/26
PFSA scores low primarily due to extremely weak financial performance (no revenue, widening losses, high cash burn, and negative equity with funding risk). Technicals also reflect a sustained downtrend. Corporate events add some offset via improved listing clarity and capital-structure actions plus a potential revenue-scaling acquisition path, but these are conditional and do not outweigh the current fundamentals.
Positive Factors
Potential diagnostics revenue scale
The proposed G3 acquisition could give Profusa access to a commercial-stage diagnostics platform with national CLIA-certified laboratories and recurring provider revenue. If financing, approvals, and debt conditions are satisfied, it would materially broaden the business beyond its pre-commercial biosensor operations.
Negative Factors
No commercial revenue and widening losses
The absence of recorded revenue indicates that Profusa has not yet reached commercial scale, while the widening net loss and negative gross profit show substantial operating costs without a revenue base. This weakens visibility into eventual margins and makes near-term operating leverage difficult to establish.
Read all positive and negative factors
Positive Factors
Negative Factors
Potential diagnostics revenue scale
The proposed G3 acquisition could give Profusa access to a commercial-stage diagnostics platform with national CLIA-certified laboratories and recurring provider revenue. If financing, approvals, and debt conditions are satisfied, it would materially broaden the business beyond its pre-commercial biosensor operations.
Read all positive factors
Profusa (PFSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.01M
Dividend YieldN/A
Average Volume (3M)3.62M
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue GrowthN/A
EPS Growth72.63%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding605,647
10 Day Avg. Volume9,819,302
30 Day Avg. Volume3,618,256
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-9.87
Price to Sales (P/S)0.00
P/FCF Ratio-16.19
Enterprise Value/Market Cap13.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.98K
Enterprise Value/Ebitda-0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Profusa Business Overview & Revenue Model
Company Description
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor c...
How the Company Makes Money
Profusa’s primary monetization model is expected to center on commercialization of its biosensing products and associated system components (e.g., implantable sensor units and external readers/wearables) and, where applicable, related services or ...
Profusa Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -35.04M | -30.73M | -4.81M | -6.00M | -13.22M | -5.05M |
| Net Income | -42.97M | -35.82M | -9.23M | -10.28M | -20.22M | -10.31M |
Balance Sheet | ||||||
| Total Assets | 1.04M | 3.77M | 3.07M | 1.89M | 1.03M | 11.36M |
| Cash, Cash Equivalents and Short-Term Investments | 719.00K | 1.78M | 191.00K | 142.00K | 78.00K | 856.00K |
| Total Debt | 14.00M | 14.81M | 48.21M | 40.40M | 31.03M | 24.02M |
| Total Liabilities | 28.17M | 30.43M | 122.28M | 111.89M | 100.80M | 95.02M |
| Stockholders Equity | -27.13M | -26.66M | -119.20M | -110.00M | -99.77M | -83.66M |
Cash Flow | ||||||
| Free Cash Flow | -21.04M | -16.26M | -2.07M | -4.40M | -7.70M | -10.69M |
| Operating Cash Flow | -20.95M | -16.25M | -2.07M | -4.40M | -7.70M | -10.69M |
| Investing Cash Flow | -7.43M | -2.01M | 0.00 | -2.00K | 0.00 | 0.00 |
| Financing Cash Flow | 28.92M | 19.84M | 2.12M | 4.47M | 6.92M | 8.75M |
Profusa Technical Analysis
Negative
5.00
Price Trends
3.80
Negative
12.03
Negative
153.42
Negative
Market Momentum
-0.72
Negative
41.42
Neutral
4.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFSA, the sentiment is Negative. The current price of 5 is above the 20-day moving average (MA) of 2.03, above the 50-day MA of 3.80, and below the 200-day MA of 153.42, indicating a bearish trend. The MACD of -0.72 indicates Negative momentum. The RSI at 41.42 is Neutral, neither overbought nor oversold. The STOCH value of 4.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PFSA.
Profusa Risk Analysis
Profusa disclosed 86 risk factors in its most recent earnings report. Profusa reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Profusa Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $111.40B | 20.91 | 10.60% | 3.34% | 9.77% | 12.28% | |
76 Outperform | $31.47B | 32.55 | 36.19% | ― | 15.54% | 77.43% | |
73 Outperform | $169.85B | 31.75 | 10.52% | 2.51% | 8.06% | -61.33% | |
54 Neutral | $526.63M | -4.04 | -165.83% | ― | 90.63% | -11.42% | |
52 Neutral | $142.89M | -11.00 | -50.27% | ― | 27.98% | 87.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $1.01M | >-0.01 | 148.25% | ― | ― | 72.63% |
* Healthcare Sector Average
PFSA
Profusa
1.50
-2,535.75
-99.94%
ABT
Abbott Laboratories
98.73
-31.57
-24.23%
DXCM
Dexcom
84.30
16.22
23.82%
MDT
Medtronic
85.51
-7.89
-8.45%
SENS
Senseonics Holdings
9.16
0.20
2.23%
OWLT
Owlet
4.73
-4.27
-47.44%
Profusa Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Profusa Amends Convertible Notes and Financing Terms
Neutral
Oct 5, 2026
On October 4, 2026, Profusa amended two senior secured convertible promissory notes originally issued to Ascent Partners Fund LLC on April 2, 2026 and April 20, 2026, with maturities in 2027, altering key economic terms of the securities. The conv...
Business Operations and StrategyPrivate Placements and Financing
Profusa Adds Secured Convertible Debt Financing Agreement
Neutral
Sep 16, 2026
On September 16, 2026, Profusa completed an additional closing under its February 11, 2025 Securities Purchase Agreement with Ascent Partners Fund LLC, issuing a senior secured convertible promissory note with a principal amount of $384,615.38 for...
Delistings and Listing ChangesRegulatory Filings and Compliance
Profusa Regains Nasdaq Compliance, Enters One-Year Monitoring
Neutral
Sep 15, 2026
On September 9, 2026, Profusa, Inc. received confirmation from Nasdaq that it had regained compliance with the Bid Price and Equity listing rules. The determination removes the immediate threat of delisting but places the company under a one-year ...
Business Operations and StrategyPrivate Placements and Financing
Profusa Secures New Convertible Note Financing Agreement
Neutral
Sep 1, 2026
On September 1, 2026, Profusa, Inc. completed an additional closing under a February 11, 2025 securities purchase agreement and issued Ascent Partners Fund LLC a senior secured convertible promissory note with a principal amount of $329,670.33 for...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Profusa Confirms Continued Compliance With Nasdaq Listing Standards
Positive
Aug 31, 2026
On August 26, 2026, Profusa disclosed that Nasdaq’s Listing Qualifications Department had initially notified the company that its recent 1-for-4 reverse stock split left it with fewer than the 500,000 publicly held shares required under Nasd...
Business Operations and StrategyPrivate Placements and Financing
Profusa Strengthens Capital Structure Through Debt-to-Equity Exchange
Positive
Aug 21, 2026
On August 12, 2026, Profusa entered into a fifth amendment to its 2025 securities purchase agreement with Ascent Partners Fund, updating the amendment effective date, adding a new optional note form and resetting the exercise price of an existing ...
Shareholder MeetingsStock Split
Profusa Announces Approved Reverse Stock Split Implementation
Neutral
Aug 14, 2026
At its annual meeting on June 23, 2026, Profusa’s stockholders approved an amendment enabling a reverse stock split at a ratio within a specified range, with the final one-for-four split later set by the chief executive officer and filed wit...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Profusa Secures Option for Major Diagnostics Acquisition
Positive
Jul 31, 2026
On July 31, 2026, Profusa entered into an Option Agreement granting it the right, but not the obligation, to acquire G3 Vision Labs and its diagnostics subsidiaries, which generated an estimated $111 million in 2025 net revenues, in a deal structu...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Profusa Plans Strategic Acquisition in Diagnostics Expansion
Positive
Jul 27, 2026
On July 27, 2026, Profusa announced it had signed a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company, aiming to form a publicly traded diagnostics business with national CLIA-ce...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.